Centum Electronics (517544) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
25 Oct, 2026Executive summary
Q4 FY25 consolidated revenue rose 24.2% YoY and 31.1% QoQ; BTS billings and domestic Defence & Space demand drove the rebound.
FY25 consolidated revenue grew 5.9%; growth was 13% on a gross basis after adding contracts accounted for on a net basis. Consolidated results remained loss-making amid subsidiary weakness.
Total order book stood at INR 17,364 Mn at March 31, 2025; management expects FY26 growth supported by BTS, EMS and new customer programs.
Financial highlights
Q4 FY25 consolidated revenue was INR 3,687 Mn, EBITDA INR 417 Mn and PAT INR 215 Mn; diluted EPS was INR 16.92.
Q4 FY25 standalone revenue was INR 2,695 Mn, EBITDA INR 468 Mn and PAT INR 296 Mn; diluted EPS was INR 22.12.
FY25 consolidated revenue was INR 11,554 Mn, EBITDA INR 967 Mn and net loss INR 19 Mn; EBITDA rose 12.6% YoY.
FY25 standalone revenue was INR 7,498 Mn, EBITDA INR 1,020 Mn and PAT INR 528 Mn; revenue grew 18.5% and PAT 45.5% YoY.
FY25 exceptional items were a net expense of INR 148.32 Mn, including a Q4 reversal of the Ausar provision of INR 44.73 Mn.
Outlook and guidance
FY26 consolidated revenue growth guidance is 18%-20%; standalone BTS and EMS revenue is targeted to grow 25%-28%, with subsidiaries expected to be roughly flat.
A consolidated EBITDA margin of 10% in FY26 was described as achievable; the margin goal is ~12% within two years.
Growth visibility draws on firm orders, customer forecasts and qualification progress; new EMS customers in semiconductor equipment and biometrics may begin firm orders in coming quarters.
Standalone CapEx of ~INR 40 crore is planned for FY26 to expand BTS and EMS capacity and capabilities.
Latest events from Centum Electronics
- Q2 revenue rose 52% YoY as the order book reached Rs 19.5 billion.517544
Q2 26/27 - Adjusted revenue grew 7%; H2 BTS deliveries are expected to support recovery.517544
Q1 24/25 - FY25 targets rely on a stronger H2 led by BTS delivery and subsidiary performance.517544
Q2 24/25 - Ausar provision and Canadian losses weighed on consolidated results despite standalone growth.517544
Q3 24/25 - Revenue and margins improved YoY, while subsidiary losses and ER&D delays persist.517544
Q1 25/26 - Standalone growth strengthened, while subsidiary losses constrained consolidated margins.517544
Q2 25/26 - Standalone growth and defense prospects offset overseas restructuring losses and impairments.517544
Q3 25/26 - Revenue and order growth were offset by overseas restructuring losses.517544
Q4 25/26 - Order book rose 31% as Q1 margins softened and reported profit included discontinued operations.517544
Q1 26/27